The global cardiac biomarker market is anticipated to grow at a CAGR of over 7% during the forecast. Rising incidences and prevalence of cardiovascular diseases (CVDs) across the globe are one of the major factors that are fuelling the market growth over the forecast period. According to the WHO, CVDs are considered one of the major causes of mortality across the globe, accounting for more than 17.3 million mortalities per year.
Browse the full report description Cardiac Biomarker Market by Type (Creatine Kinase, Troponins, Myoglobin, Ischemia Modified Albumin, and Others), By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), by Location of Testing (Laboratory Testing and Point Of Care Testing) - Global Industry Share, Growth, Competitive Analysis and Forecast Period 2020-2027 at https://www.omrglobal.com/industry-reports/cardiac-biomarkers-market
According to the American Heart Society, in 2017, CVDs are the cause of around 800 thousand mortalities in the US. Heart disease is the leading cause of mortality across the globe and the US; around 370,000 Americans lose their lives every year. The increasing prevalence of cardiovascular diseases encourages market players to focus on R&D and is expected to drive the market in the forecast period.
Market Coverage
o By Type
o By Application
o By Location Of Testing
o North America
o Europe
o Asia-Pacific
o Rest of the world
Key Questions Addressed by the Report
o Deviation from the pre-covid-19 forecast
o Most affected region and segment
Global Cardiac Biomarker Market Report Segment
By Type
By Application
By Location of Testing
Global Cardiac Biomarker Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy
@ https://www.omrglobal.com/request-sample/cardiac-biomarkers-market